Peter T Simpson

List of Publications by Year in Descending Order

112 papers	8,519 citations	46 h-index	92 g-index
130 ext. papers	10,727 ext. citations	8.6 avg, IF	7.15 L-index

#	Paper	IF	Citations
112	Whole genome deep sequencing analysis of cell-free DNA in samples with low tumour content.. *BMC Cancer*, **2022**, 22, 85	4.8	0
111	Rare germline copy number variants (CNVs) and breast cancer risk.. *Communications Biology*, **2022**, 5, 65	6.7	0
110	Blood-Derived Extracellular Vesicle-Associated miR-3182 Detects Non-Small Cell Lung Cancer Patients.. *Cancers*, **2022**, 14,	6.6	3
109	Epigenome erosion and SOX10 drive neural crest phenotypic mimicry in triple-negative breast cancer.. *Npj Breast Cancer*, **2022**, 8, 57	7.8	1
108	The Genomic Landscape of Lobular Breast Cancer. *Cancers*, **2021**, 13,	6.6	3
107	Invasive lobular carcinoma of the breast: the increasing importance of this special subtype. *Breast Cancer Research*, **2021**, 23, 6	8.3	17
106	Digital spatial profiling application in breast cancer: a users perspective. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2020**, 477, 885-890	5.1	8
105	Proteogenomic analysis of Inhibitor of Differentiation 4 (ID4) in basal-like breast cancer. *Breast Cancer Research*, **2020**, 22, 63	8.3	4
104	Pan-cancer analysis of whole genomes. *Nature*, **2020**, 578, 82-93	50.4	840
103	Breast Pathology. *Encyclopedia of Pathology*, **2020**, 71-79	0	
102	Integrin alpha-2 and beta-1 expression increases through multiple generations of the EDW01 patient-derived xenograft model of breast cancer-insight into their role in epithelial mesenchymal transition in vivo gained from an in vitro model system. *Breast Cancer Research*, **2020**, 22, 136	8.3	4
101	Clinicopathologic significance of nuclear HER4 and phospho-YAP(S) in human breast cancers and matching brain metastases. *Therapeutic Advances in Medical Oncology*, **2020**, 12, 1758835920946259	5.4	2
100	Phenotypic drift in metastatic progression of breast cancer: A case report with histologically heterogeneous lesions that are clonally related. *Clinical Case Reports (discontinued)*, **2020**, 8, 2725-2731	0.7	
99	Metaplastic breast cancers frequently express immune checkpoint markers FOXP3 and PD-L1. *British Journal of Cancer*, **2020**, 123, 1665-1672	8.7	10
98	Association of Sperm-Associated Antigen 5 and Treatment Response in Patients With Estrogen Receptor-Positive Breast Cancer. *JAMA Network Open*, **2020**, 3, e209486	10.4	2
97	Using whole-genome sequencing data to derive the homologous recombination deficiency scores. *Npj Breast Cancer*, **2020**, 6, 33	7.8	6
96	Morphologic and Genomic Heterogeneity in the Evolution and Progression of Breast Cancer. *Cancers*, **2020**, 12,	6.6	8

95	The circular RNome of primary breast cancer. *Genome Research*, **2019**, 29, 356-366	9.7	55
94	Whole-genome sequencing reveals clinically relevant insights into the aetiology of familial breast cancers. *Annals of Oncology*, **2019**, 30, 1071-1079	10.3	35
93	Diff-Quik Cytology Smears from Endobronchial Ultrasound Transbronchial Needle Aspiration Lymph Node Specimens as a Source of DNA for Next-Generation Sequencing Instead of Cell Blocks. *Respiration*, **2019**, 97, 525-539	3.7	13
92	LobSig is a multigene predictor of outcome in invasive lobular carcinoma. *Npj Breast Cancer*, **2019**, 5, 18	7.8	19
91	Phenotypic and molecular dissection of metaplastic breast cancer and the prognostic implications. *Journal of Pathology*, **2019**, 247, 214-227	9.4	42
90	Breast cancer metastasis to gynaecological organs: a clinico-pathological and molecular profiling study. *Journal of Pathology: Clinical Research*, **2019**, 5, 25-39	5.3	17
89	Characterization of a novel breast cancer cell line derived from a metastatic bone lesion of a breast cancer patient. *Breast Cancer Research and Treatment*, **2018**, 170, 179-188	4.4	2
88	Expression of MAGE-A and NY-ESO-1 cancer/testis antigens is enriched in triple-negative invasive breast cancers. *Histopathology*, **2018**, 73, 68-80	7.3	17
87	Heritable DNA methylation marks associated with susceptibility to breast cancer. *Nature Communications*, **2018**, 9, 867	17.4	52
86	Mixed ductal-lobular carcinomas: evidence for progression from ductal to lobular morphology. *Journal of Pathology*, **2018**, 244, 460-468	9.4	18
85	Multidimensional phenotyping of breast cancer cell lines to guide preclinical research. *Breast Cancer Research and Treatment*, **2018**, 167, 289-301	4.4	15
84	Thioredoxin-interacting protein is an independent risk stratifier for breast ductal carcinoma in situ. *Modern Pathology*, **2018**, 31, 1807-1815	9.8	21
83	The Brisbane Breast Bank. *Open Journal of Bioresources*, **2018**, 5,	0.9	9
82	Mutational mechanisms of amplifications revealed by analysis of clustered rearrangements in breast cancers. *Annals of Oncology*, **2018**, 29, 2223-2231	10.3	21
81	A somatic-mutational process recurrently duplicates germline susceptibility loci and tissue-specific super-enhancers in breast cancers. *Nature Genetics*, **2017**, 49, 341-348	36.3	54
80	HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. *Nature Medicine*, **2017**, 23, 517-525	50.5	444
79	Next-Generation Sequencing of Endobronchial Ultrasound Transbronchial Needle Aspiration Specimens in Lung Cancer. *American Journal of Respiratory and Critical Care Medicine*, **2017**, 196, 388-391	10.2	12
78	Flipping Pathology: Our Experience at an Australian Medical School. *Medical Science Educator*, **2017**, 27, 409-415	0.7	1

77	Molecular signatures in breast cancer. *Methods*, **2017**, 131, 135-146	4.6	32
76	Integrating Multi-omics Data to Dissect Mechanisms of DNA repair Dysregulation in Breast Cancer. *Scientific Reports*, **2016**, 6, 34000	4.9	5
75	Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration. *Nature Communications*, **2016**, 7, 12910	17.4	74
74	Understanding the functional impact of copy number alterations in breast cancer using a network modeling approach. *Molecular BioSystems*, **2016**, 12, 963-72		21
73	Personalised pathway analysis reveals association between DNA repair pathway dysregulation and chromosomal instability in sporadic breast cancer. *Molecular Oncology*, **2016**, 10, 179-93	7.9	18
72	RAD51B in Familial Breast Cancer. *PLoS ONE*, **2016**, 11, e0153788	3.7	18
71	Future Role of Molecular Profiling in Small Breast Samples and Personalised Medicine **2016**, 803-817		
70	An epithelial to mesenchymal transition programme does not usually drive the phenotype of invasive lobular carcinomas. *Journal of Pathology*, **2016**, 238, 489-94	9.4	26
69	Novel highly specific anti-periostin antibodies uncover the functional importance of the fascilin 1-1 domain and highlight preferential expression of periostin in aggressive breast cancer. *International Journal of Cancer*, **2016**, 138, 1959-70	7.5	19
68	Point Mutations in Exon 1B of APC Reveal Gastric Adenocarcinoma and Proximal Polyposis of the Stomach as a Familial Adenomatous Polyposis Variant. *American Journal of Human Genetics*, **2016**, 98, 830-842	11	153
67	Landscape of somatic mutations in 560 breast cancer whole-genome sequences. *Nature*, **2016**, 534, 47-54	50.4	1193
66	Invasive lobular carcinoma of the breast: morphology, biomarkers and 'omics. *Breast Cancer Research*, **2015**, 17, 12	8.3	170
65	ID4 controls mammary stem cells and marks breast cancers with a stem cell-like phenotype. *Nature Communications*, **2015**, 6, 6548	17.4	40
64	Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells. *Genome Research*, **2015**, 25, 814-24	9.7	52
63	Annexin A1 expression in a pooled breast cancer series: association with tumor subtypes and prognosis. *BMC Medicine*, **2015**, 13, 156	11.4	37
62	TGFβ isoforms and receptors mRNA expression in breast tumours: prognostic value and clinical implications. *BMC Cancer*, **2015**, 15, 1010	4.8	19
61	Integrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance. *Journal of Pathology*, **2015**, 237, 363-78	9.4	72
60	Using the MCF10A/MCF10CA1a Breast Cancer Progression Cell Line Model to Investigate the Effect of Active, Mutant Forms of EGFR in Breast Cancer Development and Treatment Using Gefitinib. *PLoS ONE*, **2015**, 10, e0125232	3.7	16

59	Heregulin-HER3-HER2 signaling promotes matrix metalloproteinase-dependent blood-brain-barrier transendothelial migration of human breast cancer cell lines. *Oncotarget*, **2015**, 6, 3932-46	3.3	43
58	Metastatic progression of breast cancer: insights from 50 years of autopsies. *Journal of Pathology*, **2014**, 232, 23-31	9.4	112
57	Genomic catastrophes frequently arise in esophageal adenocarcinoma and drive tumorigenesis. *Nature Communications*, **2014**, 5, 5224	17.4	176
56	Mobile DNA in cancer. Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes. *Science*, **2014**, 345, 1251343	33.3	250
55	Molecular classification of breast cancer. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2014**, 465, 1-14	5.1	106
54	Complex-based analysis of dysregulated cellular processes in cancer. *BMC Systems Biology*, **2014**, 8 Suppl 4, S1	3.5	7
53	Rad51 supports triple negative breast cancer metastasis. *Oncotarget*, **2014**, 5, 3261-72	3.3	64
52	Runx2 is a novel regulator of mammary epithelial cell fate in development and breast cancer. *Cancer Research*, **2014**, 74, 5277-5286	10.1	46
51	Meta-analysis of the global gene expression profile of triple-negative breast cancer identifies genes for the prognostication and treatment of aggressive breast cancer. *Oncogenesis*, **2014**, 3, e100	6.6	45
50	Processed pseudogenes acquired somatically during cancer development. *Nature Communications*, **2014**, 5, 3644	17.4	68
49	Mammographic and ultrasound features of invasive lobular carcinoma of the breast. *Journal of Medical Imaging and Radiation Oncology*, **2014**, 58, 1-10	1.7	50
48	A fine-scale dissection of the DNA double-strand break repair machinery and its implications for breast cancer therapy. *Nucleic Acids Research*, **2014**, 42, 6106-27	20.1	53
47	Mutations in EGFR, BRAF and RAS are rare in triple-negative and basal-like breast cancers from Caucasian women. *Breast Cancer Research and Treatment*, **2014**, 143, 385-92	4.4	43
46	Kinome profiling reveals breast cancer heterogeneity and identifies targeted therapeutic opportunities for triple negative breast cancer. *Oncotarget*, **2014**, 5, 3145-58	3.3	38
45	Evaluating the repair of DNA derived from formalin-fixed paraffin-embedded tissues prior to genomic profiling by SNP-CGH analysis. *Laboratory Investigation*, **2013**, 93, 701-10	5.9	21
44	Treatment of triple-negative breast cancer using anti-EGFR-directed radioimmunotherapy combined with radiosensitizing chemotherapy and PARP inhibitor. *Journal of Nuclear Medicine*, **2013**, 54, 913-21	8.9	59
43	Thrombospondin-4 expression is activated during the stromal response to invasive breast cancer. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2013**, 463, 535-45	5.1	44
42	miR-139-5p is a regulator of metastatic pathways in breast cancer. *Rna*, **2013**, 19, 1767-80	5.8	121

41	MicroRNA-182-5p targets a network of genes involved in DNA repair. *Rna*, **2013**, 19, 230-42	5.8	95
40	In vitro analysis of breast cancer cell line tumourspheres and primary human breast epithelia mammospheres demonstrates inter- and intrasphere heterogeneity. *PLoS ONE*, **2013**, 8, e64388	3.7	48
39	Expression profiling of archival tumors for long-term health studies. *Clinical Cancer Research*, **2012**, 18, 6136-46	12.9	25
38	Gene expression profiling of tumour epithelial and stromal compartments during breast cancer progression. *Breast Cancer Research and Treatment*, **2012**, 135, 153-65	4.4	92
37	Molecular pathology of pre-invasive breast disease in the screening setting: application in diagnosis and management. *Diagnostic Histopathology*, **2012**, 18, 64-69	0.7	
36	Calcium channel TRPV6 as a potential therapeutic target in estrogen receptor-negative breast cancer. *Molecular Cancer Therapeutics*, **2012**, 11, 2158-68	6.1	88
35	Expression and function of the protein tyrosine phosphatase receptor J (PTPRJ) in normal mammary epithelial cells and breast tumors. *PLoS ONE*, **2012**, 7, e40742	3.7	14
34	Application of molecular findings to the diagnosis and management of breast disease: recent advances and challenges. *Human Pathology*, **2011**, 42, 153-65	3.7	5
33	Tumor heterogeneity in a follicular carcinoma of thyroid: a study by comparative genomic hybridization. *Endocrine Pathology*, **2011**, 22, 103-7	4.2	5
32	Molecular aspects of breast cancer metastasis to the brain. *Genetics Research International*, **2011**, 2011, 219189	0	12
31	Molecular classification of breast cancer: is it time to pack up our microscopes?. *Pathology*, **2011**, 43, 1-8	1.6	20
30	Breast pathology: beyond morphology. *Seminars in Diagnostic Pathology*, **2010**, 27, 91-6	4.3	14
29	HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer. *Breast Cancer Research*, **2010**, 12, R46	8.3	87
28	DNA methylome of familial breast cancer identifies distinct profiles defined by mutation status. *American Journal of Human Genetics*, **2010**, 86, 420-33	11	73
27	Subtypes of familial breast tumours revealed by expression and copy number profiling. *Breast Cancer Research and Treatment*, **2010**, 123, 661-77	4.4	81
26	Gene expression profiling of formalin-fixed, paraffin-embedded familial breast tumours using the whole genome-DASL assay. *Journal of Pathology*, **2010**, 221, 452-61	9.4	57
25	Genetic Alterations in Normal and Malignant Breast Tissue **2010**, 53-66		1
24	Lobular Carcinoma in Situ **2010**, 181-199		

23	Molecular evidence for progression of microglandular adenosis (MGA) to invasive carcinoma. *American Journal of Surgical Pathology*, **2009**, 33, 496-504	6.7	66
22	Pleomorphic lobular carcinoma of the breast: molecular pathology and clinical impact. *Future Oncology*, **2009**, 5, 233-43	3.6	41
21	Molecular and morphological analysis of adenoid cystic carcinoma of the breast with synchronous tubular adenosis. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2009**, 454, 107-14	5.1	21
20	Aberrant expression of E-cadherin in lobular carcinomas of the breast. *American Journal of Surgical Pathology*, **2008**, 32, 773-83	6.7	128
19	Molecular profiling pleomorphic lobular carcinomas of the breast: evidence for a common molecular genetic pathway with classic lobular carcinomas. *Journal of Pathology*, **2008**, 215, 231-44	9.4	133
18	In situ carcinoma - can we predict which patient will come back with a recurrence?. *Cancer Cell*, **2007**, 12, 409-11	24.3	6
17	Microarray-based comparative genomic hybridisation of breast cancer patients receiving neoadjuvant chemotherapy. *British Journal of Cancer*, **2007**, 96, 341-51	8.7	46
16	FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas. *Clinical Cancer Research*, **2006**, 12, 6652-62	12.9	228
15	EGFR amplification and lack of activating mutations in metaplastic breast carcinomas. *Journal of Pathology*, **2006**, 209, 445-53	9.4	203
14	Metaplastic breast carcinomas are basal-like tumours. *Histopathology*, **2006**, 49, 10-21	7.3	244
13	Unlocking pathology archives for molecular genetic studies: a reliable method to generate probes for chromogenic and fluorescent in situ hybridization. *Laboratory Investigation*, **2006**, 86, 398-408	5.9	76
12	Gene expression analysis using filter cDNA microarrays. *Methods in Molecular Medicine*, **2006**, 120, 415-24		2
11	Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis. *Breast Cancer Research*, **2005**, 7, R1028-35	8.3	116
10	Columnar cell lesions of the breast: the missing link in breast cancer progression? A morphological and molecular analysis. *American Journal of Surgical Pathology*, **2005**, 29, 734-46	6.7	219
9	The molecular genetics of breast cancer: the contribution of comparative genomic hybridization. *Pathology Research and Practice*, **2005**, 201, 713-25	3.4	93
8	Molecular evolution of breast cancer. *Journal of Pathology*, **2005**, 205, 248-54	9.4	391
7	Pleomorphic lobular carcinoma of the breast: role of comprehensive molecular pathology in characterization of an entity. *Journal of Pathology*, **2005**, 207, 1-13	9.4	155
6	Distribution and significance of 14-3-3sigma, a novel myoepithelial marker, in normal, benign, and malignant breast tissue. *Journal of Pathology*, **2004**, 202, 274-85	9.4	60

5	P63-driven nuclear accumulation of beta-catenin is not a frequent event in human neoplasms. *Pathology Research and Practice*, **2003**, 199, 785-93	3.4	14
4	Distribution of p63, cytokeratins 5/6 and cytokeratin 14 in 51 normal and 400 neoplastic human tissue samples using TARP-4 multi-tumor tissue microarray. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2003**, 443, 122-32	5.1	201
3	Examination of tumour histopathology and gene expression in a neu/S100A4 transgenic model of metastatic breast cancer. *International Journal of Experimental Pathology*, **2003**, 84, 173-84	2.8	6
2	cDNA microarray analysis of genes associated with ERBB2 (HER2/neu) overexpression in human mammary luminal epithelial cells. *Oncogene*, **2003**, 22, 2680-8	9.2	131
1	The diagnosis and management of pre-invasive breast disease: pathology of atypical lobular hyperplasia and lobular carcinoma in situ. *Breast Cancer Research*, **2003**, 5, 258-62	8.3	93